Introducing New York Golf Club and Player Roster
Cohen Private Ventures (CPV), the family office of Steven A. Cohen, is proud to officially unveil New York Golf Club (NYGC) and its four-player roster of PGA TOUR stars featuring Rickie Fowler, Xander Schauffele, Matt Fitzpatrick and New York-native Cameron Young ahead of the inaugural 2025 TGL presented by SoFi season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402326760/en/
New York Golf Club team roster: Cameron Young, Matt Fitzpatrick, Xander Schauffele, Rickie Fowler (Photo: Business Wire)
New York is synonymous with world class, and its golf scene is no exception. Steeped in the history of the sport, with some of the greatest and most iconic courses in the world, NYGC is ready to build upon its rich legacy of golf and redefine what it means to be a golf club representing a city known for its constant reinvention. NYGC is excited to represent the tri-state area in this innovative and accessible version of the sport.
“New Yorkers expect and deserve the best, and we couldn’t be more excited to have four of the best players in the world serve as an extension of the thriving golf and sporting culture of our city and region,” said Steve Cohen, owner of the NYGC and the New York Mets. “Rickie, Xander, Matt, and Cameron’s unwavering dedication to the sport, successful track records, and passion for winning is undisputable, and we look forward to watching them compete on golf’s newest stage.”
TEAM NAME & LOGO
New York City is the greatest city in the world, and NYGC embraces the privilege and responsibility that comes with representing the five boroughs and surrounding communities. NYGC will build upon our world-class golfing and sports heritage to deliver a team New York fans can be proud of.
NYGC’s logo is inspired by New York’s state bird, the Eastern Bluebird. These birds are commonly found where forests meet fields, and particularly on golf courses. Our design features a dynamic swinging club crafted into the form of a wing with four grooves, one for each of our players. The circle pays homage to the circles on our scorecards and the iconic NYC Subway circle.
MEET THE PLAYERS
Fowler is one of the most popular players on the PGA TOUR. Since turning professional in 2009, he has recorded 10 professional wins, including the 2015 PLAYERS Championship. His most recent title came at the 2023 Rocket Mortgage Classic in July. Fowler brings a wealth of team golf experience as a veteran of five U.S. Ryder Cup teams, three U.S. Presidents Cup teams, one World Cup, Walker Cup and Palmer Cup teams from his time as an amateur player. He also represented the U.S. in the 2016 Olympic Games.
“I am thrilled to be joining New York Golf Club for the inaugural TGL season,” said Fowler. “It is an incredible opportunity to represent one of the greatest cities in the world, and I look forward to competing in 2025.”
Schauffele, currently No. 5 in the Official World Golf Ranking, has been a top-10 player in the world for the better part of the last five years and regularly placing in the Top 10 of major championships. Since turning professional in 2015, he has recorded seven PGA TOUR titles, two DP World Tour wins and an Olympic Gold Medal in Tokyo. He was named the PGA TOUR Rookie of the Year in 2016-2017 and represented the U.S. in two Presidents Cup teams and two Ryder Cup teams.
“I’ve built my career on a foundation of hard work, grit, and determination, which couldn’t better reflect the people of New York City,” said Schauffele. “It’s a true honor to both grow the game and represent this incredible city.”
Fitzpatrick became England’s first major champion since 2016 when he won the 2022 U.S. Open at The Country Club in Brookline, Massachusetts, joining Jack Nicklaus as the only players to have won a U.S. Open and U.S. Amateur at the same venue. Since turning professional in 2014, Fitzpatrick has recorded two PGA TOUR titles and eight international victories, and represented England on three European Ryder Cup teams. His most recent PGA TOUR victory came at the RBC Heritage in April 2023.
“Working with the team at Cohen Private Ventures on the launch of New York Golf Club has been an incredible experience,” said Fitzpatrick. “New York is one of the greatest cities in the world, and I could not be more excited to continue to deepen my connections there.”
The New York-native Young is quickly becoming a fan favorite on the PGA TOUR. In 2022, Young earned Rookie of the Year honors when he became the seventh player since 1980 to collect five runner-up finishes in a season, including a second-place finish at The Open Championship and tying for third at the PGA Championship. He made his debut on the Presidents Cup team in 2022. Cameron’s father David Young, recently retired after over 20 years as Sleepy Hollow Country Club’s Head Golf Professional.
“Having grown up a New Yorker, first learning to play at Sleepy Hollow, the opportunity to represent New York Golf Club feels surreal,” said Young. “Alongside Rickie, Xander, and Matt, I am confident we are going to be a highly competitive team in the upcoming TGL season.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402326760/en/
Contact information
Press
CPV and NYGC
Tiffany Galvin-Cohen
Tiffany.Galvin-Cohen@Point72.com
(203) 890-2052
TGL
Chris Reimer
Chris.Reimer@TMRWsportsgroup.com
(904) 806-6614
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom